Key Findings
Researchers at the Medical University of Vienna investigated the role of epidermal growth factor receptor (EGFR) in myeloid immune cells within the tumor microenvironment of metastatic colorectal cancer.
In preclinical models, silencing EGFR specifically in myeloid cells (including macrophages) slowed tumor growth, whereas silencing EGFR only in tumor cells did not produce a comparable effect.
EGFR in myeloid cells was found to regulate the production of factors that inhibit T cell activity, contributing to a tumor-promoting immune landscape.
The protein thrombospondin-1 (THBS1), released by myeloid cells under EGFR signaling, was identified as a potential biomarker; high levels of EGFR and THBS1 in patient data correlated with poorer prognosis.
Implications
The study suggests that anti-EGFR therapies may work in part by modulating immune cells in the tumor microenvironment, not solely by targeting cancer cells. Targeting EGFR in myeloid cells could represent a new treatment strategy for metastatic colorectal cancer.
Publication
The findings were published in the journal Cell Death & Differentiation.